San Diego, CA--December 7, 2010--Mentor Capital, Inc. (Pink Sheets:MNTR) works to provide funding to select leading-edge cancer therapy companies after careful review of their cancer science. Dr. James W. Watson, Nobel Prize winner for his co-discovery of the double-helix structure of DNA, echoed the correctness of that approach in “A Geneticist’s Cancer Crusade,” an interview recently featured in the Wall Street Journal. Dr. Watson thinks money is being spread around too much and not enough is going to the best brains. Never one to mince words, his guidance is that private money should support “cutting-edge science” not “pedantic hacks.”

Cancer Immunotherapy Index creator and Mentor Capital, CEO, Chet Billingsley, concurs and is not surprised by the blunt speaking from the former Harvard professor. “As a Harvard graduate student working with X-ray diffraction, we all knew of Professor Watson’s immensely more insightful research of bouncing X-rays through DNA to correctly posit the double-helix structure. Then as now, it takes a superb mind to manipulate the complexities of molecular biology, and Dr. Watson has no tolerance for those not up to the task.”

According to CEO Billingsley, Mentor Capital’s approach to funding the war on cancer embraces this same philosophy of seeking out and backing truly first tier cancer science. Only one in a hundred of the great sounding ideas funded by non-profit and government grants will ever make an impact on medicine. In Mentor’s experience, it is the best minds that are invariably bringing forward the breakthrough ideas. By providing public market capital to these select cancer technologies and companies Mentor Capital hopes to both advance the cancer fight and provide investors with superior returns. In the process, Mr. Billingsley would be most pleased to help Dr. Watson meet his goal of seeing cancer cured during his lifetime - and James Watson is 82.


Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site at: www.MentorCapital.com.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.

Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top